Bio-Techne Corporation (TECH) |
| 72.35 -0.12 (-0.17%) 08-28 16:00 |
| Open: | 72.4 |
| High: | 72.48 |
| Low: | 72.32 |
| Volume: | 1,630,489 |
| Market Cap: | 11,328(M) |
| PE Ratio: | 37.29 |
| Exchange: | NASDAQ |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 84.82 |
| Resistance 1: | 72.62 |
| Pivot price: | 72.31 |
| Support 1: | 71.98 |
| Support 2: | 71.58 |
| 52w High: | 72.62 |
| 52w Low: | 43.2 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
| EPS | 1.160 |
| Book Value | 13.320 |
| PEG Ratio | 0.97 |
| Gross Profit | 5.166 |
| Profit Margin (%) | 14.97 |
| Operating Margin (%) | 23.45 |
| Return on Assets (ttm) | 6.3 |
| Return on Equity (ttm) | 9.0 |
Fri, 28 Aug 2026
Bio-Techne To Be Acquired by Merck KGaA - Morningstar
Tue, 25 Aug 2026
Bio-Techne (TECH) Stock Could Be 26% Overvalued On Growth Hopes - webull.com
Mon, 24 Aug 2026
Merck’s cash deal for Bio-Techne (NASDAQ: TECH) targets late‑2026 close - Stock Titan
Mon, 24 Aug 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corpo - mykxlg.com
Sat, 22 Aug 2026
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders - The Malone Telegram
Tue, 18 Aug 2026
Is Wall Street Bullish or Bearish on Bio-Techne Stock? - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |